The general objective of the proposed regulation, which complements the ongoing revision of the EU pharmaceutical legislation, is to strengthen the security of supply and the availability of critical ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

New research from Bayes Business School, in collaboration with biopharmaceuticals company Merck KGaA, suggests member states ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...